Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1176/appi.ajp.2015.15030380 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Drug Development.
Alzheimers Dement
December 2024
Massachusetts General Hospital, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Preclinical Alzheimer's disease (AD) trials can involve multiple years of follow-up and burdensome procedures for older individuals. Optimizing the design and conduct of these trials requires input from participants and their families. Since 2020, the Alzheimer's Clinical Trials Consortium (ACTC) Research Participant Advisory Board has provided input on study attributes including: participant and study partner compensation, consent language, and result communication tools.
View Article and Find Full Text PDFDrug Development.
Alzheimers Dement
December 2024
Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
Women account for almost two-thirds of Alzheimer's disease (AD) cases, yet evidence significantly less clinical benefit from recently deployed amyloid-lowering therapies. To close this disparity gap, there is an urgent need to identify biological drivers of sex differences in the manifestation and clinical response to AD therapeutics. A recent review of multi-omic studies of AD reported >75% of studies showed female-specific changes at the molecular level (vs.
View Article and Find Full Text PDFDrug Development.
Alzheimers Dement
December 2024
Brigham and Women's Hospital and Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
The most recent Alzheimer's clinical trials, including those which reported successful outcomes, use neuroimaging biomarkers of both amyloid and tau for screening participants and demonstrating a treatment effect on pathology. Some of these trials, notably Lecanemab, hint at a potential sex bias in treatment outcome, alluding to major implications for clinical practice when recommending treatment options. Sex differences in treatment response are not surprising given that women are at greater risk of progression to AD dementia, particularly if they carry APOEe4.
View Article and Find Full Text PDFDementia Care Research and Psychosocial Factors.
Alzheimers Dement
December 2024
Yonsei University, Wonju, Gangwon-do, Korea, Republic of (South).
Background: Self-rated health status goes beyond a mere indicator of one's well-being, encompassing biological, social, and functional aspects. It has emerged as a significant variable in predicting mortality. Against this backdrop, understanding the impact of subjective health status on anxiety symptoms is crucial for individuals with dementia.
View Article and Find Full Text PDFDementia Care Research and Psychosocial Factors.
Alzheimers Dement
December 2024
Aging Research Center, Karolinska Institutet and Stockholm University, Stockholm, Sweden.
Background: Worldwide, ∽40% of dementia cases are preventable by interventions to target major modifiable risk factors. In the multimodal interventions to delay dementia and disability in rural China (MIND-China), we aim to test the effect of multimodal intervention programs on maintaining cognitive and physical function among rural-dwelling older adults and discuss about challenges and opportunities for a multidomain intervention study in a rural population.
Method: MIND-China targets people who are aged 60-79 years and living in rural communities (52 villages) in Shandong.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!